Identifying key biomarkers and therapeutic candidates for post-COVID-19 depression through integrated omics and bioinformatics approaches

Abstract

Depression, the leading cause of disability worldwide, is known to be exacerbated by severe acute respiratory syndrome coronavirus 2 infection, worsening coronavirus disease 2019 (COVID-19) outcomes. However, the mechanisms and treatments for this comorbidity are not well understood.

Keywords

• covid-19
• major depressive disorder
• neuroinflammation
• neuroimmune response
• transcriptional and posttranscriptional regulation